C91.42 Hairy cell leukemia, in relapse

Name of the Condition

• Hairy cell leukemia, in relapse
• ICD-10 Code: C91.42

Summary

Hairy cell leukemia in relapse is a hematologic condition where abnormal B lymphocytes with hair-like projections reappear or become clinically active after a period of remission. This state indicates a return of disease activity, with potential recurrence of cytopenias (low blood cell counts) and bone marrow infiltration. Relapse may occur months or years after initial treatment, requiring reassessment and potential therapeutic adjustments.

Causes

The exact cause of hairy cell leukemia relapse is not fully understood, but it involves genetic mutations in B lymphocytes that persist or reemerge despite prior treatment. Contributing factors may include residual disease, treatment resistance, or incomplete eradication of abnormal cells during initial therapy. The underlying genetic drivers of the disease remain unchanged, but relapse reflects a resurgence of clonal proliferation.

Risk Factors

• Increasing age (most common in adults over 50)
• Male gender (slight predominance)
• Family history of hematologic malignancies (less clearly established)
• Prior treatment response (e.g., history of remission and relapse)
• Duration of remission (shorter remission periods may increase relapse risk)

Symptoms

• Recurrence of fatigue and weakness
• Renewed susceptibility to infections due to low white blood cell counts
• Easy bruising or bleeding from low platelet counts
• Abdominal discomfort or splenomegaly (enlarged spleen)
• Unexplained weight loss or fever (less common)

Diagnosis

Diagnosis involves a physical examination, followed by blood tests to assess cell counts and identify abnormal lymphocytes with characteristic "hairy" projections. Bone marrow biopsy may confirm relapse by demonstrating increased infiltration of hairy cells. Flow cytometry or immunohistochemistry can help detect residual or recurrent disease, and imaging studies (e.g., ultrasound) may evaluate splenic size.

Treatment Options

Treatment for relapsed hairy cell leukemia may include reinitiation of prior effective therapies (e.g., purine analogs) or alternative agents (e.g., monoclonal antibodies). Response to treatment is monitored via blood counts, bone marrow assessments, and symptom resolution. Clinical judgment guides timing and choice of therapy based on disease activity and patient factors.

Prognosis and Follow-Up

Prognosis for relapsed hairy cell leukemia varies, but many patients respond to retreatment. Ongoing monitoring (e.g., periodic blood tests, bone marrow evaluations) is essential to detect further relapse or progression. Long-term follow-up ensures timely intervention and management of complications.

Complications

• Cytopenias (anemia, neutropenia, thrombocytopenia) leading to fatigue, infection, or bleeding
• Splenomegaly causing abdominal discomfort or early satiety
• Increased risk of secondary malignancies (rare)
• Treatment-related toxicities (e.g., myelosuppression, infections)

Lifestyle & Prevention

No specific lifestyle measures prevent relapse, but general health maintenance supports overall well-being. Patients should avoid infections (e.g., vaccinations, hygiene) and report new symptoms promptly. Regular medical follow-up is critical for early detection of relapse.

When to Seek Professional Help

Seek medical attention for:

• Worsening fatigue, unexplained weight loss, or fever
• Recurrent or severe infections
• Easy bruising, bleeding, or petechiae
• Abdominal pain or rapid splenic enlargement
• New or persistent symptoms suggesting disease activity

Tips for Medical Coders

Document the presence of relapse (e.g., clinical or laboratory evidence of disease recurrence) to support code assignment. Ensure coding aligns with the patient’s current clinical status and treatment response. Note that relapse implies prior remission; documentation should clarify the timeline and evidence of disease return.